2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
India-Taiwan cooperation can drive sustainable growth
India`s auto industry to boost investment in South A...
Rashtriya Vigyan Puraskar 2025 announced, honours In...
Stronger India-Brazil ties to give Global South a bi...
India emerges as strong performing market for global...
eClerx reports strong Q2 FY2025-26 results
Petroleum Secretary to Inaugurate India`s Premier Gl...
Quote on FII flows 26th Oct 2025 from Dr. VK Vijayak...
Direct flights between Agartala-Bagdogra and Agartal...
Rapid 5G rollout, adoption lay foundation for India?...
